A potential drug targeting Alzheimer’s and Schizophrenia, developed by Hyderabad-based Suven Life Sciences, has commenced the Phase I clinical trial in the US.
According to the company, the new chemical entity (NCE) is a potent, selective, brain penetrant and an orally active histamine for the treatment of cognitive dysfunction associated with the age-related diseases, which do not have effective curative treatments at present.
It has completed all the pre-clinical, safety and early toxicological studies. Suven has submitted data for the Investigational New Drug Application, a request for the US Food and Drug Administration authorisation to conduct the Phase 1 clinical trial of the investigational drug, a press release said on Monday.
The company has 11 therapeutic drug candidates in pre-clinical state of development, targeting dementia, major depressive disorder, Huntington’s disease, Parkinson’s and obesity, said Venkat Jasti, CEO of Suven.
Interestingly, in the past few months, a couple of global research studies have pointed to encouraging results from potential drugs to treat Alzheimer’s.